Superior efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) compared with ritonavir (RTV) boosted atazanavir (ATV) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatmentnai naive women with HIV-1 infection (ARIA Study)

被引：0
|
作者：
Orrell, C. [1 ]
Hagins, D. [2 ]
Belonosova, E. [3 ]
Porteiro, N. [4 ]
Walmsley, S. [5 ]
Falco, V. [6 ]
Man, C. [7 ]
Aylott, A. [8 ]
Buchanan, A. [7 ]
Wynne, B. [9 ]
Vavro, C. [7 ]
Aboud, M. [10 ]
Smith, K. [7 ]
机构：
[1] Univ Cape Town, Desmond Tutu HIV Fdn, Cape Town, South Africa
[2] Chatham Cty Hlth Dept, Savannah, GA USA
[3] Orel Reg Ctr AIDS, Oryol, Russia
[4] Fdn IDEAA, Buenos Aires, DF, Argentina
[5] Univ Hlth Network, Toronto, ON, Canada
[6] Hosp Valle De Hebron, Barcelona, Spain
[7] ViiV Healthcare, Res Triangle Pk, Durham, NC USA
[8] GlaxoSmithKline, Stockley Pk, West Drayton, England
[9] ViiV Healthcare, Philadelphia, PA USA
[10] ViiV Healthcare, Brentford, England
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2016年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
THAB0205LB
引用
收藏
页数：1
相关论文
共 7 条
  • [1] Efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed-dose combination (FDC) compared with ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naive women with HIV-1 infection (ARIA study): subgroup analyses
    Johnson, Margaret
    Gatey, Caroline
    Manosuthi, Weeraweet
    Lazzarin, Adriano
    Podzamczer, Daniel
    Man, Choy
    Aylott, Alicia
    Buchanan, Annie
    Wynne, Brian
    Vavro, Cindy
    Aboud, Michael
    Smith, Kim
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [2] Non-inferior efficacy of dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine (TDF/FTC) fixed-dose combination in antiretroviral treatment-naive adults with HIV-1 infection-48-week results from the GEMINI studies
    Cahn, P.
    Sierra Madero, J.
    Arribas, J.
    Antinori, A.
    Ortiz, R.
    Clarke, A.
    Hung, C. -C.
    Rockstroh, J.
    Girard, P. -M.
    Man, C.
    Sievers, J.
    Currie, A.
    Underwood, M.
    Tenorio, A.
    Pappa, K.
    Wynne, B.
    Gartland, M.
    Aboud, M.
    Smith, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 : 156 - 156
  • [3] Simplification to abacavir/lamivudine (ABC/3TC) + atazanavir (ATV) from tenofovir/emtricitabine (TDF/FTC) plus ATV/ritonavir (r) maintains viral suppression and improves bone biomarkers: 48 weeks ASSURE study results.
    Wohl, David A.
    Bhatti, Laveeza
    Small, Catherine B.
    Edelstein, Howard E.
    Zhao, Henry
    Margolis, David A.
    Ross, Lisa L.
    Shaefer, Mark S.
    PHARMACOTHERAPY, 2013, 33 (10): : E211 - E212
  • [4] Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
    Orrell, Catherine
    Hagins, Debbie P.
    Belonosova, Elena
    Porteiro, Norma
    Walmsley, Sharon
    Falco, Vicenc
    Man, Choy Y.
    Aylott, Alicia
    Buchanan, Ann M.
    Wynne, Brian
    Vavro, Cindy
    Aboud, Michael
    Smith, Kimberly Y.
    LANCET HIV, 2017, 4 (12): : E536 - E546
  • [5] Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is non-inferior to dolutegravir plus tenofovir/emtricitabine (DTG plus TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies
    Orkin, C.
    Porteiro, N.
    Berhe, M.
    Dretler, R.
    Viciana, P.
    Tseng, Y.
    Oprea, C.
    Johnson, M.
    Kulagin, V.
    Man, C.
    Sievers, J.
    Currie, A.
    Underwood, M.
    Tenorio, A.
    Pappa, K.
    Wynne, B.
    Aboud, M.
    Smith, K.
    Gartland, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [6] Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study (vol 4, pg e546, 2017)
    Orrell, C.
    Hagins, D. P.
    Belonosova, E.
    LANCET HIV, 2017, 4 (12): : E535 - E535
  • [7] Comparison of efficacy and safety of a switch to fixed-dose combination FTC/TDF-TAF/RPV versus fixed-dose combination 3TC/ABC/DTG in HIV-1-infected, treatment experienced and virologically suppressed patients: a cohort study
    Lagi, F.
    Kiros, S. T.
    Botta, A.
    Meli, M.
    Borchi, B.
    Bartoloni, A.
    Sterrantino, G.
    HIV MEDICINE, 2019, 20 : 83 - 83
1